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Abstract
Rationale Anorexia nervosa (AN) is a serious psychiatric dis-
order with high morbidity and mortality. There are no
established pharmacological treatments and the neurobiology
of the condition is poorly understood. Previous studies using
magnetic resonance spectroscopy (MRS) have shown that AN
may be associated with reductions in indices of brain gluta-
mate; however, at conventional field strengths (≤3 T), it is
difficult to separate glutamate from its precursor and metabo-
lite, glutamine.
Objectives The objective of the present study was to use high
field (7 T) MRS to measure concentrations of glutamate, in
three separate brain voxels, in women with AN.
Methods We studied 13 female participants with AN and 12
healthy female controls who underwent MRS scanning at 7 T
with voxels placed in anterior cingulate cortex, occipital cor-
tex and putamen. Neurometabolites were calculated using the
unsuppressed water signal as a reference and corrected for
individual cerebrospinal fluid concentration in the voxel.
Results We found that participants with AN had significantly
lower concentrations of glutamate in all three voxels (mean
reduction 8%, p = 0.002) but glutamine levels were not al-
tered. Concentrations of N-acetylaspartate, creatine, GABA
and glutathione were also unchanged. However, inositol was
lower in AN participants in anterior cingulate (p = 0.022) and
occipital cortex (p = 0.002).
Conclusions Women with AN apparently have widespread
reductions in brain glutamate. Further work will be needed
to assess if this change has pathophysiological relevance or
whether it is a consequence of the many physical changes
produced in AN by food restriction.
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Introduction
Anorexia nervosa (AN) is a serious mental illness with a high
morbidity and mortality. The characteristic feature of AN is an
overwhelming fear of gaining weight coupled with strict mea-
sures to reduce net calorie intake; however, emotional and
cognitive disturbances commonly accompany the illness
(Fairburn and Harrison 2003; Zipfel et al. 2015). The best
current treatments emphasise weight restoration and specific
psychotherapies but outcomes are often unsatisfactory, partic-
ularly in adult patients (Smink et al. 2012). Antidepressant
medication is widely used in AN but has no specific effect
on the core disorder and is often unhelpful in relieving depres-
sion (Aigner et al. 2011). The development of effective phar-
macological treatments for AN requires a better knowledge of
underlying neurobiology (Zipfel et al. 2015).
Glutamate is the main excitatory neurotransmitter in brain
and is implicated in a number of psychiatric disorders relevant
to AN, including depression and obsessive compulsive disor-
der (Yüksel and Öngür 2010; Naaijen et al. 2015). It is
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possible to measure glutamate concentrations in the brain non-
invasively with magnetic resonance spectroscopy (MRS) but
at conventional field strengths, there is difficulty
distinguishing glutamate from its precursor and metabolite,
glutamine. For this reason, a composite measure called ‘Glx’
is often employed (Yüksel and Öngür 2010). Some, but not
all, previous studies in AN participants have reported low Glx
levels in frontal brain regions (Ohrmann et al. 2004; Castro-
Fornieles et al. 2007; Joos et al. 2011; Blasel et al. 2012) such
as anterior cingulate cortex. The availability ofMRS at 7 Tesla
(7 T) permits clear separation of glutamate and glutamine
resonances as well as a more precise quantification of
neurometabolites (Tkáč et al. 2009).
The aim of the present study was to use high field MRS to
assess brain glutamate concentrations in patients with AN.We
selected three voxels for this purpose, occipital cortex (OCC),
anterior cingulate cortex (ACC) and putamen (PUT). The
OCC is often used for MRS studies because of the lack of
field inhomogeneity in this brain region. The OCC has not
been linked to anorexia nervosa but elevated levels of gluta-
mate have sometimes been reported in OCC in depressed
patients (Yüksel and Öngür 2010). The ACC and PUT (the
latter as part of the striatum) have been implicated in the neural
circuitry underpinning AN (Kaye et al. 2009).
Methods
Participants
All participants gave full written informed consent to the study
which was approved by the National Research Ethics Service
Committee, South-Central Oxford C. We obtained usable
MRS data from 13 female participants (mean age 29.1 years,
range 18–41 years) with longstanding AN (mean duration
12.7 years, range 3–26 years) as defined by the Diagnostic
and Statistical Manual of Mental Disorders Fifth Edition
(DSM-5) and 12 healthy female controls (27.3 years, range
20–41 years). Exclusion criteria for the AN participants were
psychosis or substance dependence, contraindication to MRS
imaging, pregnancy or breastfeeding, or history of claustro-
phobia. Similar exclusion criteria were applied to the healthy
controls with the addition of any current or past history of
psychiatric disorder on DSM-5 and concurrent psychotropic
medication.
Ten of the AN participants had current additional current
diagnoses of major depression and one also had panic disor-
der. The mean score of the AN participants on the Eating
Disorder Examination Questionnaire (EDE-Q) was 3.7 (range
0.8–6.1) and on the Hamilton Rating Scale for Depression
(HAM-D) 20.7 (range 3–36). The corresponding values for
the controls were EDE-Q, 0.5 (0.06–1.38) and HAM-D, 0.5
(0–3). The mean BMI of the AN participants was 15.3 (range
13.3–18.2) and that of the controls was 21.3 (range 18.6–
25.3). Eight of the AN participants were inpatients and eight
were taking psychotropic medications, including mirtazapine
15 mg, fluoxetine 20 and 40 mg, sertraline 100 and 200 mg,
citalopram 40 mg, bupropion 75 mg, paroxetine 40 mg,
olanzapine 5 and 10 mg, lorazepam 2.5–5 mg, zopiclone
7.5 mg and melatonin 3 mg.
Magnetic resonance spectroscopy
Participants underwent proton (1H) MRS scanning at the
Functional Magnetic Resonance Imaging of the Brain
(FMRIB) Centre in Oxford. Scanning was performed on a 7-
T Siemens MAGNETOM scanner (Siemens, Erlangen,
Germany) equipped with a Nova Medical 32 channel receive
array head coil. Spectra were measured from three voxels, in
the ACC (20 × 20 × 20 mm), in the OCC (20 × 20 × 20mm)
and in the PUT (10 × 16 × 20mm) (Fig. 1). Voxels were
positioned manually by reference to 1-mm isotropic T1-
MPRAGE image. First- and second-order shims were first
adjusted by gradient-echo shimming (Shah et al. 2009). The
second step involved only fine adjustment of first order shims
using FASTMAP (Gruetter and Tkáč 2000). Spectra were
acquired using a stimulated echo acquisition mode
(STEAM) pulse sequence (TE = 11 ms, TR = 5 s, number of
transients = 64) with variable power radiofrequency pulses
with optimised relaxation delays (VAPOR) water suppression
and outer volume saturation (Emir et al. 2012). Unsuppressed
water spectra acquired from the same voxel were used to re-
move residual eddy current effects and to reconstruct the
phased array spectra.
Metabolites were quantified using LCModel (Provencher
2001). The model spectra of aspartate (Asp), ascorbate/
vi tamin C (Asc), glycerophosphochol ine (GPC),
phosphocholine (PC), creatine (Cr), phosphocreatine (PCr),
γ-amino-butyric acid (GABA), glucose (Glc), glutamine
(Gln), glutamate (Glu), glutathione (GSH), myo-inositol
(m y o - I n s ) , N - a c e t y l a s p a r t a t e ( N A A ) , N -
acetylaspartylglutamate (NAAG), phosphoethanolamine
(PE), scyllo-inositol (scyllo-Ins) and taurine (Tau) were gen-
erated based on previously reported chemical shifts and cou-
pling constants (Govindaraju et al. 2000; Tkáč 2008) by using
GAMMA/PyGAMMA simulation library of VESPA for car-
rying out the density matrix formalism [VErsatile Simulation,
Pulses and Analysis 9]. Simulations were performed with the
same RF pulses and sequence timings as that on the 7-T sys-
tem. A macromolecule spectrum acquired from the OCC,
using an inversion recovery sequence (TR = 3 s,
TE = 11 ms, inversion time TI = 0.685 s), was included in
the model spectra. Metabolite concentrations were obtained
relative to an unsuppressed water spectrum acquired from
the same VOI assuming a water content of 82% for occipital
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cortex and anterior cingulate and 78% for the putamen
(Gelman et al. 2001).
The MPRAGE images were segmented using FAST
(FMRIB’s Automated Segmentation Tool, part of the FSL
toolbox) to determine CSF fraction (fCSF) in the voxels
(Zhang et al. 2001). Concentrations were then corrected for
CSF fraction with the following formula: [Mcorr] = [M].
(1/[1 − fCSF]), where [Mcorr] = corrected concentration and
[M] = metabolite concentration from LCModel output.
Metabolites quantified with Cramer-Rao lower bounds
(CRLB), estimated error of the metabolite quantification
>30% were classified as not detected. As a secondary filter
to select reliable metabolite concentrations, only metabolites
quantified with CRLB ≤30% in at least half of the spectra
from a brain region were reported (see Table 1 for mean
CRLB values for each metabolite included in the analysis).
If the correlation between two metabolites was consistently
high (correlation coefficient <−0.5) in a given region, their
sum was reported, such as NAA + NAAG (tNAA, total
NAA) and Cr + PCr (tCr, total creatine).
Statistics
Statistical analyses were performed in SPSS version 22.
Differences in metabolite concentrations between AN partic-
ipants and controls were determined using repeated measures
analysis of variance (ANOVA), with ‘region’ (ACC vs PUT
vs OCC) as a within-subject factor and ‘diagnosis’ (AN vs
control) as a between subject factor. Significant interactions
were followed up with unpaired t tests (two tailed).
Correlations were carried out using Pearson’s product
moment.
Results
Four MRS spectra (two for the ACC, one for the OCC and
PUT) were excluded due to their quality, leaving 11 AN par-
ticipants and 10 controls who had valid glutamate and gluta-
mine data for all three brain regions The repeated measures
ANOVA for glutamate showed a main effect of diagnosis
(F = 13.7; df = 1.19; p = 0.002) but no interaction with region
(F = 0.053; df = 2.19; p = 0.95) indicating a reduction of
glutamate in AN participants in all three voxels (Fig. 2). In
contrast, there was no main or interactive effect of diagnosis
on glutamine levels (F = 2.99; df = 1.19; p = 0.10 and
F = 0.023; df = 1.19; p = 0.88) (Table 1). Consistent with
these findings, there was a significant main effect of diagnosis
on the ratio of glutamine to glutamate (F = 6.28; df = 1.19;
p = 0.021) with higher ratios in the AN participants.
Similar analyses of other neurometabolites showed no sig-
nificant main or interactive effects of diagnosis on total N-
Fig. 1 Voxel placement and
representative spectra from the
anterior cingulate cortex (ACC),
occipital cortex (OCC) and
putamen (PUT). Each acquired
spectrum (64 averages) is overlaid
with the metabolite fit from
LCModel (red line) with major
peaks labeled. The difference
between the metabolite fit and
underlying spectrum is shown
below as a residual, which
remains small and uniform
indicating a high quality spectral
fit. tCR total creatine, Ins myo-
Inositol, Cho choline, Glu
glutamate, NAA N-acetylaspartate
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acetylaspartate (NAA), total creatine, GABA, or glutathione.
There were, however, a significant main effect of diagnosis
and a significant diagnosis by region interaction for inositol
(F = 7.62; df = 1.19; p = 0.012 and F = 4.07; df = 2.38;
p = 0.025, respectively) where inositol levels in ACC and
OCC were lower in AN participants (see Table 1). In the AN
participants, there was no significant correlation between glu-
tamate level in any of the brain regions studied and total score
on the EDE-Q and HAM-D (all p values >0.1).
Discussion
Because of the small numbers of participants studied, this
study should be regarded as a pilot investigation. Within this
limitation, we found that glutamate levels in AN participants
were diminished in all three voxels studied. Interestingly, con-
centrations of the glutamate precursor and metabolite, gluta-
mine, were not significantly changed which resulted in a sig-
nificantly increased ratio of glutamine to glutamate in AN.
This suggests that the conversion of glutamine to glutamate
in glutamate neurons is diminished in AN (Yüksel and Öngür
2010). It is also possible, however, that the availability of
glutamate might be generally decreased if amino acids are
being used as an energy source in AN patients, though this
does not seem to be the case from measures of amino acids in
plasma in AN (Moyano et al. 1998). A number of lower field
strength MRS studies have examined Glx levels in anterior
brain regions in AN with conflicting results; however, some
have reported diminished Glx concentrations (Ohrmann et al.
2004; Castro-Fornieles et al. 2007; Joos et al. 2011; Blasel
et al. 2012). Our study suggests that diminished glutamate is
the key contributor to this decrease in Glx.
Many neurobiological changes have been reported in AN
patients relative to healthy controls and such changes often
reflect the effects of weight loss (Phillipou et al. 2014). The
same could clearly be true of the lowered brain glutamate
levels we have observed. Further studies will be needed in
recovered patients as well as those at high risk of AN to de-
termine whether lowered glutamate activity might play a path-
ophysiological role in AN. The participants in this study were
at different stages of treatment and were taking a variety of
medications. It will be important that future work attempts to
study participants with less variation in these factors.
It is also commonly reported that AN patients have de-
creased cortical greymatter volumewhich could be associated
Table 1 Magnetic resonance spectroscopy (MRS) measures (μmol/g)
and the Cramer–Rao lower bound (CRLB) (%) for glutamate, glutamine,
total N-acetylaspartate (tNAA), total creatine (tCr), γ-aminobutyric acid
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Fig. 2 Mean (SEM) glutamate levels in 11 female patients with anorexia
nervosa (AN) and 10 female healthy controls (CON) in three brain
regions, anterior cingulate cortex (ACC), occipital cortex (OCC) and
putamen (PUT). There is a main effect of diagnosis on glutamate levels,
independent of region (F = 13.7; df = 1.19; p = 0.002)
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with altered levels of brain neurochemicals (Phillipou et al.
2014). However, we took this possibility into account by
correcting for CSF volume in the voxel. Also, we found no
reduction in AN in total NAA which is believed to be an
important marker of grey matter integrity (Birken and
Oldendorf 1989). MRS glutamate levels can fluctuate with
the menstrual cycle (Batra et al. 2008). Hence, it is also pos-
sible that the changes we have seen reflect alterations in sex
steroid levels in the AN participants. In this context, it is im-
portant to note that we studied female participants only and
although the incidence of AN inmales is generally regarded as
about tenfold less than that in women, under-diagnosis in men
may occur (Raevuori et al. 2014). Clearly, we are not able to
extrapolate our MRS findings in women to men with AN.
AN patients frequently suffer from comorbid depression
and major depression has been associated with lowered Glx
levels, particularly in anterior brain regions (Yüksel and
Öngür 2010; Luykx et al. 2012). Thus, accompanying depres-
sive symptomatology is a possible explanation for lowered
glutamate in AN. Against this, in depressed patients, Glx
levels in OCC have been reported as either normal or in-
creased (Yüksel and Öngür 2010) whereas in the AN patients
the reduction in glutamate also involved the OCC. Further,
there was no correlation in the AN participants between de-
pression severity (measured by the HAM-D) and glutamate
level. As is common in the treatment of severe AN, many
participants were also taking psychotropic medication, princi-
pally selective serotonin reuptake inhibitors (SSRIs).
However, in a sample of depressed patients, we found no
effect of SSRI treatment on MRS glutamate measures
(Godlewska et al. 2015) which makes concomitant treatment
with SSRIs an unlikely explanation for our findings.
However, other patients were taking different kinds of psy-
chotropic medication and in future work it will be important to
study AN participants who are medication free.
The use of MRS at 7 T also permitted the accurate mea-
surement of several other neurometabolites. With one excep-
tion, there was no difference between AN participants and
healthy controls. However, there was a decrease in inositol
in AN in two of the three brain regions studied. We made no
correction for multiple comparisons and therefore this finding
must be treated with particular caution. However, some, but
not all, previous MRS studies have also reported lower levels
of inositol in cortical regions in AN patients (Roser et al. 1999;
Ohrmann et al. 2004; Castro-Fornieles et al. 2007; Joos et al.
2011; Blasel et al. 2012). These investigations have linked the
low inositol levels to the metabolic effects of starvation or to
concomitant depression (Roser et al. 1999; Ohrmann et al.
2004).
In conclusion, our study is the first, as far as we are aware,
to measure glutamate in AN with MRS at 7 T and demon-
strates what appears to be a rather generalised reduction in
brain glutamate levels. Further work will be needed to assess
whether treatments manipulating brain glutamate levels might
be of value in AN management.
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